Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) EBIT: 2015-2023

Historic EBIT for Cellectis (CLLS) over the last 9 years, with Sep 2023 value amounting to -$20.7 million.

  • Cellectis' EBIT rose 24.43% to -$20.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$73.4 million, marking a year-over-year increase of 32.34%. This contributed to the annual value of -$89.7 million for FY2022, which is 13.35% up from last year.
  • As of Q3 2023, Cellectis' EBIT stood at -$20.7 million, which was up 12.49% from -$23.6 million recorded in Q2 2023.
  • Over the past 5 years, Cellectis' EBIT peaked at $14.4 million during Q1 2020, and registered a low of -$42.4 million during Q3 2021.
  • Over the past 3 years, Cellectis' median EBIT value was -$24.6 million (recorded in 2021), while the average stood at -$25.6 million.
  • As far as peak fluctuations go, Cellectis' EBIT skyrocketed by 162.34% in 2020, and later plummeted by 238.13% in 2021.
  • Quarterly analysis of 5 years shows Cellectis' EBIT stood at -$38.5 million in 2019, then decreased by 1.74% to -$39.2 million in 2020, then soared by 37.29% to -$24.6 million in 2021, then skyrocketed by 76.95% to -$5.7 million in 2022, then increased by 24.43% to -$20.7 million in 2023.
  • Its EBIT stands at -$20.7 million for Q3 2023, versus -$23.6 million for Q2 2023 and -$23.4 million for Q1 2023.